Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Blood Plasma for Age-Related Cognitive Decline
NCT04566757Phase 1Unknown
- Sponsor
- American Academy of Regenerative Medicine
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Biologic
01
Overview
Phase 1, open-label, single-arm trial of human umbilical cord blood plasma in age-related cognitive decline, sponsored by American Academy of Regenerative Medicine. Primary endpoint: Safety of Umbilical Cord Blood Plasma Infusion at 6 months. Status: unknown.
02
Drugs
human umbilical cord blood plasma
03
Conditions
age-related cognitive decline
Beyond the preview
Go deeper on NCT04566757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04566757.